Daewon Pharmaceutical Second Quarter 2025 Earnings: ₩131 loss per share (vs ₩33.44 loss in 2Q 2024)

Daewon Pharmaceutical (KRX:003220) Second Quarter 2025 Results

Key Financial Results

• Revenue: ₩143.9b (up 4.3% from 2Q 2024).
• Net loss: ₩2.81b (loss widened by 306% from 2Q 2024).
• ₩131 loss per share (further deteriorated from ₩33.44 loss in 2Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Daewon Pharmaceutical Earnings Insights

Looking ahead, revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea.

Performance of the South Korean Pharmaceuticals industry.

The company's shares are down 2.3% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Daewon Pharmaceutical has 4 warning signs we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.